Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has been selected to enter the Euronext's Tech40 label, recognizing the best performing Tech SMEs listed on Euronext markets.
Companies within the Tech 40 label are technology stocks listed on Euronext markets, operating in life sciences, eco-industries or Technology, Media, and Telecom (TMT). An independent group of European experts annually selects 40 great companies regarding their business, financial and stock market performance.
Laurent Levy, Nanobiotix CEO commented: "We are very pleased to have been selected to enter the Euronext's Tech40 Label as one of the most promising companies. This rewards our historic commitment to innovation and should enable us to further increase our visibility among institutional investors worldwide
About NANOBIOTIX: www.nanobiotix.com
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges.
The Company's first-in-class, proprietary lead technology, NanoXray, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, the Company's Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO ISIN: FR0011341205; Bloomberg: NANO: FP). The Company's Headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA, and european affiliates in Spain and Germany.
Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number D.17-0470 on April 28, 2017 as well as in its 2017 annual financial report filed with the French Financial Markets Authority on March 29, 2018 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180426006355/en/
Contacts:
Nanobiotix
Sarah Gaubert, +33 (0)1 40 26 07 55
Director, Communication Public Affairs
sarah.gaubert@nanobiotix.com / contact@nanobiotix.com
or
Noël Kurdi, +1 (646) 241-4400
Director, Investor Relations
noel.kurdi@nanobiotix.com / investors@nanobiotix.com
or
Media relations
France Springbok Consultants
Marina Rosoff, +33 (0)6 71 58 00 34
marina@springbok.fr
or
United States RooneyPartners
Marion Janic, +1 (212) 223-4017
mjanic@rooneyco.com
